Search

everythinglearnresearchcommunity

for

Search:↓

Pimecrolimus cream is not effective for treating alopecia areata.

Certain gene variations in EGF and EGFR may increase the risk of alopecia areata in Koreans.

PRDX5 enzyme may contribute to alopecia areata by affecting oxidative stress and autoimmunity.

Dermoscopy helped diagnose a rare skin disease which slightly improved with treatment.

Some people with Frontal Fibrosing Alopecia may be allergic to a common sunscreen ingredient.

A new mutation in the STING protein causes a disease with lupus-like symptoms and responds well to a specific inhibitor treatment.

Blocking JAK1 or JAK3 helps reverse hair loss in a mouse model of alopecia areata.

Azelaic acid in a special gel is more effective against skin fungi than regular azelaic acid.

A Taiwanese patient had hair loss and skin bumps without the usual gene mutation, suggesting other genetic factors might be involved.

Baricitinib is effective and safe for treating severe alopecia areata.

Most patients with alopecia areata did not achieve lasting hair regrowth despite treatment.

Certain factors like allergies, nail problems, and hair loss patterns can predict how well someone with patchy hair loss will respond to skin cream treatments.

Medicaid coverage for alopecia areata treatments is inconsistent and often limited.

A 93-year-old woman developed a rare scalp condition after therapy, which improved with steroids, not antibiotics.

Dermatologists vary widely in testing practices for alopecia areata, often exceeding guideline recommendations.

Baricitinib maintains significant hair regrowth in severe alopecia areata over three years.

Relapsing hepatitis A can cause prolonged abnormal liver tests even without symptoms.

Thalidomide works best for skin lupus not helped by antimalarials, but has many side effects; other treatments are less effective, especially if patients also have systemic lupus.

Patients with a specific genetic variant have more severe alopecia areata and higher recurrence rates.

Alopecia areata is an autoimmune condition causing hair loss due to the immune system attacking hair follicles, often influenced by genetics and stress.

Baricitinib helped most teenagers with severe hair loss regrow hair and had mild side effects.

Ritlecitinib may cause severe musculoskeletal pain in some alopecia universalis patients.

The research identified unique metabolic activities in immune cells associated with hair loss in Alopecia Areata.

Baricitinib works better in adolescents than adults for treating severe alopecia areata.

Oral betamethasone works faster than oral tofacitinib for hair regrowth in alopecia areata.

Laminin-511 is involved in psoriasis development and can be regulated by cannabinoid receptor type 1.

Combining ficlatuzumab and gefitinib can cause severe scarring hair loss.

Excluding alopecia and mucous membrane components from the CLASI-A score reduces its effectiveness in capturing important disease activity.

The study suggests that a specific type of immune cell, memory-like NK cells, may increase during active hair loss in Alopecia areata.